Moderna : Verdict in a few weeks
>A road show logically focused on COVID-19 - We organised last Friday a road show with Stéphane Bancel, CEO of Moderna. This presentation was an opportunity to review notably the state of development of its vaccine for COVID-19 currently in phase III but also on the resultant opportunities. Following this road show, we reiterate our Buy recommendation ahead of the first interim results, in addition to our target price of € 86. An ambitious phase III trial...Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.